Elliot Israel

List of Publications by Year
in descending order

103 papers	6,931 citations	81900 39 h-index	62596 80 g-index
104 all docs	104 docs citations	104 times ranked	7842 citing authors

#	Article	IF	Citations
1	Nebulizer Use by Black and Latinx Adults with Moderate to Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 517-524.e2.	3.8	4
2	The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. Journal of Allergy and Clinical Immunology, 2022, 149, 488-516.e9.	2.9	24
3	Socioeconomic impact of COVID-19 and willingness to be vaccinated in African American/Black and Hispanic/Latinx adults. Journal of the National Medical Association, 2022, 114, 182-192.	0.8	4
4	Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1036-1045.	5.6	39
5	Key Issues in Pediatric and Adult Severe Asthma: Staying Grounded as Biologics Take Us to New Heights. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 420-421.	3.8	0
6	Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. Journal of Asthma, 2022, 59, 2201-2217.	1.7	18
7	Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma. New England Journal of Medicine, 2022, 386, 1505-1518.	27.0	40
8	Deconstructing the Way We Use Pulmonary Function Test Race-Based Adjustments. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 972-978.	3.8	13
9	The Impact of Insulin Resistance on Loss of Lung Function and Response to Treatment in Asthma. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1096-1106.	5.6	28
10	Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation. Contemporary Clinical Trials, 2021, 100, 106228.	1.8	24
11	A randomized, open-label, pragmatic study to assess reliever-triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: Design and methods of the PREPARE trial. Contemporary Clinical Trials, 2021, 101, 106246.	1.8	14
12	Responsiveness to Parenteral Corticosteroids and Lung Function Trajectory in Adults with Moderate-to-Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 841-852.	5.6	14
13	The association of plasma IL-6 with measures of asthma morbidity in a moderate-severe pediatric cohort aged 6-18 years. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2916-2919.e2.	3.8	11
14	Geography, generalisability, and susceptibility in clinical trials. Lancet Respiratory Medicine,the, 2021, 9, 330-332.	10.7	12
15	Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research Program. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 882-892.	5.6	39
16	Effect of COVID-19 on asthma exacerbation. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2896-2899.e1.	3.8	31
17	Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. Genome Medicine, 2021, 13, 66.	8.2	21
18	PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. Journal of Allergy and Clinical Immunology, 2021, 147, 1594-1601.	2.9	27

#	Article	IF	Citations
19	Mechanisms and Treatment of the Diverse Presentations of Acute Wheezing and Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2635-2637.	3.8	1
20	Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. Journal of Allergy and Clinical Immunology, 2021, 148, 790-798.	2.9	147
21	Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: Results from SARP-3. Journal of Allergy and Clinical Immunology, 2021, 148, 752-762.	2.9	30
22	The endogenous circadian system worsens asthma at night independent of sleep and other daily behavioral or environmental cycles. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	28
23	Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. New England Journal of Medicine, 2021, 385, 1656-1668.	27.0	183
24	Estimated Ventricular Size, Asthma Severity,Âand Exacerbations. Chest, 2020, 157, 258-267.	0.8	4
25	Development and initial validation of the Asthma Severity Scoring System (ASSESS). Journal of Allergy and Clinical Immunology, 2020, 145, 127-139.	2.9	19
26	Nocturnal bilevel positive airway pressure for the treatment of asthma. Respiratory Physiology and Neurobiology, 2020, 274, 103355.	1.6	3
27	A randomized, placeboâ€controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Clinical and Experimental Allergy, 2020, 50, 1342-1351.	2.9	30
28	Real-world experiences with generating real-world evidence: Case Studies from PCORI's pragmatic clinical Studies program. Contemporary Clinical Trials, 2020, 98, 106171.	1.8	4
29	Implementing the guidelines: What do you do when the rubber hits the road?. Journal of Allergy and Clinical Immunology, 2020, 146, 1271-1274.	2.9	10
30	Personalizing Precision Medicine. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1614-1615.	3.8	1
31	The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations. Journal of Biopharmaceutical Statistics, 2020, 30, 1026-1037.	0.8	11
32	HSD3B1 genotype identifies glucocorticoid responsiveness in severe asthma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2187-2193.	7.1	27
33	Eosinophilâ€derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2085-2088.	5.7	11
34	Baseline sputum eosinophilÂ+ neutrophil subgroupsâ€™ clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort. Journal of Allergy and Clinical Immunology, 2020, 146, 222-226.	2.9	25
35	Adherence to adding inhaled corticosteroids to rescue therapy in a pragmatic trial with adults with asthma. Annals of Allergy, Asthma and Immunology, 2020, 124, 487-493.e1.	1.0	8
36	Distinct associations of sputum and oral microbiota with atopic, immunologic, and clinical features in mild asthma. Journal of Allergy and Clinical Immunology, 2020, 146, 1016-1026.	2.9	46

#	Article	IF	Citations
37	Susceptibility to exacerbations in Black adults with asthma. Journal of Asthma, 2019, 56, 704-710.	1.7	4
38	A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2019, 143, 316-324.e7.	2.9	34
39	Reply. Journal of Allergy and Clinical Immunology, 2019, 144, 873-874.	2.9	0
40	Biologics, Clinical Context, and the Asthmas. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1437-1439.	3.8	2
41	Increased extracellular maspin levels after mechanical compression inÂvitro or allergen challenge inÂvivo. Journal of Allergy and Clinical Immunology, 2019, 144, 1116-1118.e4.	2.9	6
42	Asthma and Corticosteroid Responses in Childhood and Adult Asthma. Clinics in Chest Medicine, 2019, 40, 163-177.	2.1	36
43	Loss of bronchoprotection with ICS plus LABA treatment, Î²-receptor dynamics, and the effect of alendronate. Journal of Allergy and Clinical Immunology, 2019, 144, 416-425.e7.	2.9	6
44	What Patients Can Tell Us About Their Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 906-907.	3.8	1
45	Challenges in assessing the efficacy of systemic corticosteroids for severe wheezing episodes in preschool children. Journal of Allergy and Clinical Immunology, 2019, 143, 1934-1937.e4.	2.9	2
46	Adapting clinical trial design to maintain meaningful outcomes during a multicenter asthma trial in the precision medicine era. Contemporary Clinical Trials, 2019, 77, 98-103.	1.8	4
47	Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Journal of Allergy and Clinical Immunology, 2019, 143, 2052-2061.	2.9	65
48	Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2019, 143, 799-803.e2.	2.9	22
49	Predictors of inhaled corticosteroid taper failure in adults with asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1335-1337.e3.	3.8	0
50	The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation. Nature Communications, 2018, 9, 1603.	12.8	58
51	Anti-IgE or Anti-IL5: That Is the Question. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 782-784.	3.8	3
52	Asthma Step-Down Strategies: Perhaps the Patient Should Decide?. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 644-645.	3.8	1
53	Income is an independent risk factor for worse asthma outcomes. Journal of Allergy and Clinical Immunology, 2018, 141, 754-760.e3.	2.9	59
54	Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 907-915.e7.	3.8	36

#	Article	IF	Citations
55	Bacterial biogeography of adult airways in atopic asthma. Microbiome, 2018, 6, 104.	11.1	93
56	Association of free vitamin D3 concentrations and asthma treatment failures in the VIDA Trial. Annals of Allergy, Asthma and Immunology, 2018, 121, 444-450.e1.	1.0	7
57	Flexibility and strength training in asthma: A pilot study. Journal of Asthma, 2018, 55, 1376-1383.	1.7	5
58	Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. Journal of Clinical Investigation, 2018, 128, 997-1009.	8.2	337
59	Race is associated with differences in airway inflammation in patients with asthma. Journal of Allergy and Clinical Immunology, 2017, 140, 257-265.e11.	2.9	39
60	Natural killer cellâ€“mediated inflammation resolution is disabled in severe asthma. Science Immunology, 2017, 2, .	11.9	76
61	Asthma Yardstick. Annals of Allergy, Asthma and Immunology, 2017, 118, 133-142.e3.	1.0	26
62	KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. New England Journal of Medicine, 2017, 376, 1911-1920.	27.0	159
63	Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1439-1448.	5.6	87
64	Severe and Difficult-to-Treat Asthma in Adults. New England Journal of Medicine, 2017, 377, 965-976.	27.0	357
65	Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. Journal of Allergy and Clinical Immunology, 2017, 140, 63-75.	2.9	222
66	Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 302-313.	5.6	346
67	ALX receptor ligands define a biochemical endotype for severe asthma. JCI Insight, 2017, 2, .	5.0	29
68	Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS ONE, 2017, 12, e0178112.	2.5	31
69	Insulin resistance modifies the association between obesity and current asthma in adults. European Respiratory Journal, 2016, 48, 403-410.	6.7	92
70	Association Between Insomnia and AsthmaÂBurden in the Severe Asthma Research Program (SARP) III. Chest, 2016, 150, 1242-1250.	0.8	51
71	Individualized therapy for persistent asthma in young children. Journal of Allergy and Clinical Immunology, 2016, 138, 1608-1618.e12.	2.9	208
72	Alternative Macrophage Activation Is Increased in Asthma. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 467-475.	2.9	141

#	Article	IF	Citations
73	Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2016, 137, 1566-1576.e5.	2.9	142
74	Vitamin D3 treatment of vitamin Dâ€“insufficient asthmatic patients does not alter immune cell function. Journal of Allergy and Clinical Immunology, 2016, 138, 286-289.e9.	2.9	7
75	Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler. ERJ Open Research, 2016, 2, 00106-2015.	2.6	11
76	IL-13 Augments Compressive Stressâ€“Induced Tissue Factor Expression in Human Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 524-531.	2.9	35
77	Impact of Age and Sex on Outcomes and Hospital Cost of Acute Asthma in the United States, 2011-2012. PLoS ONE, 2016, 11, e0157301.	2.5	57
78	Compressive Stress Causes an Unjamming Transition and an Epithelialâ€“Mesenchymal Transition in the Airway Epithelium in Asthma. Annals of the American Thoracic Society, 2016, 13, S102-S102.	3.2	5
79	Impact of Age and Sex on Response to Asthma Therapy. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 551-558.	5.6	45
80	Update on reslizumab for eosinophilic asthma. Expert Opinion on Biological Therapy, 2015, 15, 1531-1539.	3.1	20
81	Anticholinergic vs Long-Acting Î²-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma. JAMA - Journal of the American Medical Association, 2015, 314, 1720.	7.4	61
82	Unjamming and cell shape in the asthmatic airwayÂepithelium. Nature Materials, 2015, 14, 1040-1048.	27.5	484
83	Asthma Is More Severe in Older Adults. PLoS ONE, 2015, 10, e0133490.	2.5	80
84	Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma. PLoS ONE, 2015, 10, e0145476.	2.5	49
85	Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. International Journal of COPD, 2014, 9, 1163.	2.3	18
86	Effect of Vitamin D₃on Asthma Treatment Failures in Adults With Symptomatic Asthma and Lower Vitamin D Levels. JAMA - Journal of the American Medical Association, 2014, 311, 2083.	7.4	236
87	Severe Asthma: Pragmatic Clinical Lumping and Time for Investigational Splitting. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 619-620.	5.6	2
88	LTC4 synthase polymorphism modifies efficacy of botanical seed oil combination in asthma. SpringerPlus, 2014, 3, 661.	1.2	3
89	Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respiratory Medicine,the, 2014, 2, 44-53.	10.7	44
90	Interleukin-17â€“producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nature Medicine, 2014, 20, 54-61.	30.7	515

#	Article	IF	Citations
91	Characterization of factors associated with systemic corticosteroid use in severe asthma: Data from the Severe Asthma Research Program. Journal of Allergy and Clinical Immunology, 2014, 133, 915-918.	2.9	27
92	Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. Journal of Allergy and Clinical Immunology, 2014, 133, 1280-1288.	2.9	247
93	Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting Î² agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respiratory Medicine,the, 2014, 2, 204-213.	10.7	100
94	Exhaled breath condensate eicosanoid levels associate with asthma and its severity. Journal of Allergy and Clinical Immunology, 2013, 132, 547-553.	2.9	89
95	Integrating real-life studies in the global therapeutic research framework. Lancet Respiratory Medicine,the, 2013, 1, e29-e30.	10.7	102
96	Characteristics of Perimenstrual Asthma and Its Relation to Asthma Severity and Control. Chest, 2013, 143, 984-992.	0.8	78
97	Determinants of Exhaled Breath Condensate pH in a Large Population With Asthma. Chest, 2011, 139, 328-336.	0.8	61
98	Genetics and the variability of treatment response in asthma. Journal of Allergy and Clinical Immunology, 2005, 115, S532-S538.	2.9	29
99	Effects of montelukast and beclomethasone on airway function and asthma control. Journal of Allergy and Clinical Immunology, 2002, 110, 847-854.	2.9	111
100	Inhaled Albuterol, but Not Intravenous Lidocaine, Protects Against Intubation-induced Bronchoconstriction in Asthma. Anesthesiology, 2000, 93, 1198-1204.	2.5	66
101	A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature, 2000, 406, 998-1001.	27.8	330
102	Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ: British Medical Journal, 1999, 319, 87-90.	2.3	227
103	Agonist-induced lipoxin A4 generation: Detection by a novel lipoxin A4-ELISA. Lipids, 1993, 28, 1047-1053.	1.7	54